Skip to main content
. Author manuscript; available in PMC: 2021 Mar 19.
Published in final edited form as: J Am Coll Cardiol. 2020 Jan 28;75(3):320–332. doi: 10.1016/j.jacc.2019.11.025

Table 3.

Pharmacokinetic characteristics of cannabinoids

Cannabinoid Compound Substrate Pathway Affected Metabolism Pathways
Inhibitor Inducer
Cannabidiol CYP3A4
CYP2C19
CYP3A4
CYP2D6
CYP2C8/9/19
CYP1A1/2
CYP1B1
CYP2B6
Tetrahydrocannabinol CYP2C9
CYP3A4
CYP3A
CYP2D6
CYP2C9
CYP2B6
CYP1A1/2
Cannabinol CYP2C9
CYP3A4
CYP3A
CYP2D6
CYP2C9
CYP2B6
Synthetic Cannabinoids CYP2C9
CYP1A2
CYP2D6
CYP1A
CYP2C8/9/19
CYP3A